围手术期高血压患者94例麻醉处理

围手术期高血压患者９４例麻醉处理李美娅，刘宏伟，马兴隆高血压是麻醉和手术的主要危险因素。剧烈的血压波动如不及时处理可危及重要脏器。因此，完善的镇痛效果和稳定的血压水平是保证重要脏器灌注，安全渡过围手术期的重要条件。现将我院高血压患者９４例的麻醉处理讨...     

370例冠心病手术麻醉及围术期处理的体会

我院从１９９０年７月至１９９４年１２月施行冠心病外科手术３７０例,兹对麻醉及围术期处理的体会报告如下。临床资料３７０例中男３３０例（８９２％）、女４０例（１０８％）,年龄≥６０岁者１００例（２７０％）。术前心功能Ⅲ级及以下者１６４例（４４３％...     

小儿手外科的围手术期麻醉护理

目的：总结小儿手外科手术中围手术期的麻醉护理要点。方法回顾性分析2011年1月-2012年12月852例小儿手外科手术麻醉护理配合。结果全部患者顺利完成手术,无不良反应和并发症的发生。结论提高手术室护理人员对小儿患者的重视,根据小儿患者的生理、心理特点,有针对性地采取相应护理措施是确保小儿手术成功的关键。     

TUVP术围手术期的生理变化与麻醉

目的探讨TUVP术(经尿道前列腺电汽化术)的手术和麻醉安全性。方法观察289例TUVP术和耻骨上前列腺除术患围手术期BP(血压)、P(心率)变化，比较两组输血量、手术时间和术前健康状况分级。结果TUVP术手术时间短，创伤轻微，无一例输血，围术期BP、P较平稳，变化和缓。结论TUVP术对人体生理代谢影响小，手术麻醉安全性高，但术前准备和治疗仍应重视。     

原发性甲状旁腺功能亢进症围手术期麻醉处理的体会

甲状旁腺肿瘤或增生所致的原发性甲状旁腺功能亢进症（以下简称甲旁亢），因钙、磷代谢障碍可导致机体一系列病理生理改变。手术切除有内分泌功能的肿瘤组织是治疗甲旁亢的有效手段，兹对围术期的麻醉处理报告如下。临床资料全组２２例，男５例、女１７例，年龄１１～５５...     

颈椎手术围手术期的麻醉处理

随着脊柱内固定器械种类和使用方法的进展,颈椎手术范围和种类日益增多,对麻醉技术的要求已不仅仅满足于无痛、无意识和肌松等基本要求.麻醉医帅已参与到脊柱外科患者围手术期处理的全程中.现将近年来颈椎手术麻醉经验教训及颈椎于术麻醉方而的进展综述如下.     

Chinese herbal medicine in the treatment of chronic kidney disease

Chronic kidney disease (CKD) is a worldwide public health issue with poor outcomes and high cost. There is growing evidence that some of the adverse outcomes of CKD can be prevented or delayed by early treatment using angiotensin II-converting enzyme inhibitors and angiotensin II-receptor blockers. A great amount of the world's population has been using traditional Chinese herbal medicine (TCHM) for treatment of CKD and has accumulated their experience for years. In this article, the knowledge and the therapeutic principles of traditional Chinese medicine in the treatment of CKD are briefly reviewed. The efficacy of several TCHMs, supported by either clinical evidence or experimental studies, is presented. The future direction for the study of Chinese herbal medicines in CKD is discussed.     

Traditional Chinese herbal medicine and anaesthesia

An increasing number of people in the western world are using traditional Chinese herbal medicines. There are concerns that these Chinese medicines may contain potentially toxic ingredients and contaminants such as heavy metals. Undeclared conventional western drugs such as the non-steroidal anti-inflammatory and antihistamine drugs, steroids and oral hypoglycaemic agents are frequently added to Chinese herbal medicines. The constituents of the herbal products can cause adverse effects. The anaesthetist should be aware of the potential adverse effects of the herbal products, their contaminants and also of undeclared additives. The potential for drug interactions, coagulopathy and organ dysfunction caused by traditional Chinese herbal medicines has important anaesthetic implications.     

中西医防治围术期低体温的研究进展

围术期患者常发生低体温。目前防治围术期低体温(IPH)多采用物理保温、升温的方法。中医认为,体温降低与机体阳气温煦失司、营卫失调、阴阳失衡以及脏腑功能受损有关。从创伤出血证候出发,围术期发生的低体温与寒邪内侵导致的阳气不舒关系最为密切。按照中医的阳气不舒理论进行论治可采用调畅气血、舒展全身阳气的方法防治术中、术后低体温,方法包括艾灸、穴位贴敷、穴位按摩、中药热熨等。本文对中医、西医防治IPH的进展进行综述,并展望中西医结合防治IPH的前景,以期为预防IPH提供更加有效的方法,达到促进患者快速康复的目的。     

A boy with recurrent hemorrhagic cystitis during treatment with Chinese herbal medicine

An 11 year-old boy experienced nine episodes of hemorrhagic cystitis while he was receiving Sho-saiko-to or Saiko-seikan-to, Chinese herbal medicines, for the treatment of atopic dermatitis. Each episode of hemorrhagic cystitis subsided spontaneously when the Chinese herbal medicine was discontinued. He did not develop symptoms of hemorrhagic cystitis during the administration of Keishika-ryukotu-borei-to and Goreisan. To our knowledge, hemorrhagic cystitis caused by Saiko-seikan-to has not been reported previously. Ohgon, one of the constituents of Sho-saiko-to and Saiko-seikan-to, was considered to have caused the hemorrhagic cystitis in this patient. Received: October 30, 2001 / Accepted: February 2, 2002     

Effect of Chinese herbal medicine on overactive bladder

Gosha-jinki-gan (GJG), a traditional Chinese medicine, is known to be potentially effective for urinary disturbance. For the clinical evaluation of Gosha-jinki-gan, we administered GJG for 6 weeks to elderly male patients with overactive bladder (OAB) and assessed its efficacy and tolerability. In this study, 30 male patients with over 6 months of OAB symptoms had received 2.5 g GJG mixture x 3/day. After 6 weeks of treatment, the efficacy, safety, and tolerability were assessed. We evaluated International Prostate Symptom Score (I-PSS), Overactive Bladder Symptom Score (OABSS), quality of life (QOL), maximal urinary flow rate (Qmax), average urinary flow rate (Qave), incidence of urinary incontinence, and post-void residual before and after treatment. We observed significant improvements in I-PSS (15.2 +/- 1.0 vs. 12.0 +/- 0.9, p < 0.0001), OABSS (7.5 +/- 0.6 vs. 4.9 +/- 0.5, p < 0.0001), and QOL score (4.4 +/- 1.0 vs. 3.3 +/- 1.1, p < 0.0001, Wilcoxon rank sum test). GJG was significantly effective in improving urgency, micturition frequency, nocturia, and urinary incontinence (p < 0.05). However, Qmax, Qave, and post void residual did not significantly change. Mild adverse effects were observed in 3 cases. The symptoms were diarrhea, nausea, and urinary frequency. These data suggest that Gosha-jinki-gan may be a new potential therapeutic agent for OAB without deterioration of voiding function in men with benign prostatic obstruction (BPO).     

补肾祛湿中药联合多沙唑嗪治疗慢性附睾炎的临床研究

目的:了解补肾祛湿中药联合多沙唑嗪治疗慢性附睾炎的临床疗效。方法:64例慢性附睾炎患者随机均分为2组,每组32例。对照组仅服用多沙唑嗪,治疗组采用补肾祛湿中药联合多沙唑嗪治疗,每组患者接受药物治疗4周。使用慢性附睾炎症状指数评分表(CESI)、焦虑自评量表(SDS)、抑郁自评量表(SAS)等对治疗前后临床症状进行评估,并评价其疗效。结果:两组经治疗后,在CESI总均分、疼痛评分以及生活质量评分上皆有显著性改善(P<0.05);治疗组与对照组相比疗效更佳,差异有显著性(P<0.05)。治疗后两组患者在SAS及SDS评分上皆有显著性降低(P<0.05),但两组间比较无显著性差异(P>0.05)。结论:单独使用多沙唑嗪及补肾祛湿中药联合多沙唑嗪对慢性附睾炎皆有明显的临床疗效,但联合用药是一种更佳的治疗方法。